Efficacy and Biomarker Analysis of Camrelizumab in Combination with Apatinib in Patients with Advanced Nonsquamous NSCLC Previously Treated with Chemotherapy.

Caicun ZhouYina WangJun ZhaoGongyan ChenZhihua LiuKangsheng GuMeijuan HuangJianxing HeJianhua ChenZhiyong MaJifeng FengJianhua ShiXinmin YuYing ChengYu YaoYuan ChenRen-Hua GuoXiaoyan LinZhehai WangGuanghui GaoQuanren WangWeixia LiXinfeng YangLihong WuJun ZhangShengxiang Ren

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)

Combined apatinib and camrelizumab showed encouraging antitumor activity and acceptable toxicity in chemotherapy-pretreated patients with advanced nonsquamous NSCLC. Patients with STK11/KEAP1 mutation might derive more benefits from this combination. We will validate these results in an ongoing phase III trial (NCT04203485).

Keyphrases

phase iii
open label
small cell lung cancer
clinical trial
locally advanced
phase ii
advanced non small cell lung cancer
double blind
placebo controlled
study protocol
randomized controlled trial
squamous cell carcinoma
radiation therapy
rectal cancer
newly diagnosed